Skip to main content

Table 3 Course of septic shock (propensity-weighted) from baseline to day 6 by steroid use at baseline and randomized treatment

From: Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial

Ā 

DrotAA and steroid use

DrotAA and no steroid use

Placebo and steroid use

Placebo and no steroid use

Change in cardiovascular sequential organ failure assessment

Ā Ā Ā Ā 

Mean (SD)

āˆ’2.8 (1.6)

āˆ’2.7 (1.6)

āˆ’2.8 (1.6)

āˆ’2.9 (1.6)

Median (25th, 75th percentile)

āˆ’4 (āˆ’4,-1)

āˆ’4 (āˆ’4,-1)

āˆ’4 (āˆ’4,-1)

āˆ’4 (āˆ’4,-2)

Minimum, maximum

āˆ’4, 1

āˆ’4, 1

āˆ’4, 1

āˆ’4, 1

Vasopressor-free days

Ā Ā Ā Ā 

Mean (SD)

2.5 (2.0)

2.7 (2.1)

2.4 (2.0)

2.9 (2.0)

Median (25th, 75th percentile)

3 (0,4)

3 (0,5)

3 (0,4)

4 (1,5)

Minimum, maximum

0, 6

0, 6

0, 6

0, 6

  1. DrotAA, drotrecogin-alfa activated.